Identification and evaluation of immune and targeted therapies for acral melanoma
Active Project Grant Awarded Last action
- Award ID
- HT9425261E239
- Recipient
-
H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. UEI DVHKP4N619V9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,435,737
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 4% complete
- Place of performance
- Tampa, FL 33612, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $1,435,737 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify and evaluate immune and targeted therapies for acral melanoma. Work is performed in Tampa, Florida, with a period of performance extending through August 31, 2030. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for battlefield and clinical settings. Awards under this program typically range from $100,000 to $20 million for consortium projects, with average award periods of three to four years.
Quick answers
Who received award HT9425261E239?
HT9425261E239 was awarded to H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. by Defense Health Agency (Department of Defense) on September 1, 2026.
How much is award HT9425261E239 worth?
$1,435,737 has been obligated on HT9425261E239.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award